Lecankitug

莱康奇塔单抗

Report date: 2026/01/05 14:24:19

Base Information

Drug NameLecankitug
Drug Alias NameLZM－012LZM012XKH004XKH-004
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionInterleukin-17F inhibitorsInterleukin 17A inhibitors
TargetsInterleukin-17FInterleukin 17A
Therapy Area/IndicationsPlaque psoriasisPsoriasisSpondylitis, Ankylosing
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusNDA/BLA
Highest Status in ChinaNDA/BLA
Originator CompaniesLivzon Pharmaceutical Group IncBeijing Kanova Biomedical Technology Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesLivzon Pharmaceutical Group IncBeijing Kanova Biomedical Technology Co LtdLivzon Mabpharm Inc
Inactive CompaniesN/A
Active IndicationsPlaque psoriasisPsoriasisSpondylitis, Ankylosing
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A